Sanofi India Limited (SANOFI.NS)
INR 6082.6
(-0.65%)
INR 6082.6
(-0.65%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 6.02 Billion INR | -2.85% |
| 2022 | 6.2 Billion INR | -34.29% |
| 2021 | 9.44 Billion INR | 97.74% |
| 2020 | 4.77 Billion INR | 15.31% |
| 2019 | 4.14 Billion INR | 8.83% |
| 2018 | 3.8 Billion INR | 16.75% |
| 2017 | 3.26 Billion INR | 9.76% |
| 2016 | 2.97 Billion INR | -7.62% |
| 2015 | 3.21 Billion INR | 21.96% |
| 2014 | 2.63 Billion INR | -0.59% |
| 2013 | 2.65 Billion INR | 50.11% |
| 2012 | 1.76 Billion INR | -7.6% |
| 2011 | 1.91 Billion INR | 23.34% |
| 2010 | 1.55 Billion INR | -1.52% |
| 2009 | 1.57 Billion INR | -5.29% |
| 2008 | 1.66 Billion INR | 15.08% |
| 2007 | 1.44 Billion INR | -14.69% |
| 2006 | 1.69 Billion INR | 16.69% |
| 2005 | 1.45 Billion INR | -2.3% |
| 2004 | 1.48 Billion INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 1.36 Billion INR | -0.8% |
| 2024 Q2 | 1.03 Billion INR | -24.45% |
| 2023 Q1 | 1.9 Billion INR | 45.45% |
| 2023 FY | 6.02 Billion INR | -2.85% |
| 2023 Q2 | 1.22 Billion INR | -35.45% |
| 2023 Q4 | 1.37 Billion INR | -9.35% |
| 2023 Q3 | 1.51 Billion INR | 23.6% |
| 2022 FY | 6.2 Billion INR | -34.29% |
| 2022 Q2 | 1.2 Billion INR | -49.5% |
| 2022 Q3 | 1.3 Billion INR | 8.72% |
| 2022 Q4 | 1.3 Billion INR | 0.0% |
| 2022 Q1 | 2.38 Billion INR | 163.72% |
| 2021 Q1 | 1.45 Billion INR | 18.62% |
| 2021 Q3 | 5.29 Billion INR | 197.14% |
| 2021 Q4 | 904 Million INR | -82.94% |
| 2021 Q2 | 1.78 Billion INR | 22.21% |
| 2021 FY | 9.44 Billion INR | 97.74% |
| 2020 FY | 4.77 Billion INR | 15.31% |
| 2020 Q4 | 1.23 Billion INR | -7.45% |
| 2020 Q3 | 1.32 Billion INR | -2.49% |
| 2020 Q2 | 1.36 Billion INR | 59.6% |
| 2020 Q1 | 854 Million INR | -12.23% |
| 2019 Q4 | 973 Million INR | -23.14% |
| 2019 Q1 | 929 Million INR | 17.15% |
| 2019 Q2 | 974 Million INR | 4.84% |
| 2019 Q3 | 1.26 Billion INR | 29.98% |
| 2019 FY | 4.14 Billion INR | 8.83% |
| 2018 Q2 | 996 Million INR | 20.73% |
| 2018 Q4 | 793 Million INR | -33.47% |
| 2018 FY | 3.8 Billion INR | 16.75% |
| 2018 Q1 | 825 Million INR | 8.55% |
| 2018 Q3 | 1.19 Billion INR | 19.68% |
| 2017 Q3 | 1.16 Billion INR | 57.8% |
| 2017 Q2 | 737 Million INR | 22.83% |
| 2017 Q1 | 600 Million INR | 14.07% |
| 2017 FY | 3.26 Billion INR | 9.76% |
| 2017 Q4 | 760 Million INR | -34.65% |
| 2016 Q4 | 526 Million INR | -36.55% |
| 2016 FY | 2.97 Billion INR | -7.62% |
| 2016 Q3 | 829 Million INR | -3.72% |
| 2016 Q2 | 861 Million INR | 4.24% |
| 2016 Q1 | 826 Million INR | -31.28% |
| 2015 Q3 | 725 Million INR | 12.93% |
| 2015 FY | 3.21 Billion INR | 21.96% |
| 2015 Q4 | 1.2 Billion INR | 65.79% |
| 2015 Q1 | 645 Million INR | -30.2% |
| 2015 Q2 | 642 Million INR | -0.47% |
| 2014 Q2 | 575 Million INR | 11.22% |
| 2014 Q3 | 620 Million INR | 7.83% |
| 2014 FY | 2.63 Billion INR | -0.59% |
| 2014 Q4 | 924.1 Million INR | 49.05% |
| 2014 Q1 | 517 Million INR | -44.16% |
| 2013 Q4 | 925.8 Million INR | 20.39% |
| 2013 Q2 | 512 Million INR | 15.32% |
| 2013 Q1 | 444 Million INR | -0.8% |
| 2013 FY | 2.65 Billion INR | 50.11% |
| 2013 Q3 | 769 Million INR | 50.2% |
| 2012 Q3 | 513 Million INR | 26.67% |
| 2012 Q4 | 447.6 Million INR | -12.75% |
| 2012 Q2 | 405 Million INR | 1.0% |
| 2012 Q1 | 401 Million INR | 11.12% |
| 2012 FY | 1.76 Billion INR | -7.6% |
| 2011 Q2 | 497 Million INR | 0.0% |
| 2011 Q4 | 360.88 Million INR | -34.15% |
| 2011 Q3 | 548 Million INR | 10.26% |
| 2011 FY | 1.91 Billion INR | 23.34% |
| 2010 FY | 1.55 Billion INR | -1.52% |
| 2009 FY | 1.57 Billion INR | -5.29% |
| 2008 FY | 1.66 Billion INR | 15.08% |
| 2007 FY | 1.44 Billion INR | -14.69% |
| 2006 FY | 1.69 Billion INR | 16.69% |
| 2005 FY | 1.45 Billion INR | -2.3% |
| 2004 FY | 1.48 Billion INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Abbott India Limited | 12.01 Billion INR | 49.809% |
| Cipla Limited | 41.21 Billion INR | 85.372% |
| Gland Pharma Limited | 7.72 Billion INR | 21.951% |
| GlaxoSmithKline Pharmaceuticals Limited | 5.89 Billion INR | -2.193% |
| Kopran Limited | 509.56 Million INR | -1083.175% |
| Marksans Pharma Limited | 3.13 Billion INR | -92.19% |
| NGL Fine-Chem Limited | 413.16 Million INR | -1359.216% |
| Pfizer Limited | 5.51 Billion INR | -9.354% |
| SMS Pharmaceuticals Limited | 498.26 Million INR | -1110.011% |
| TTK Healthcare Limited | 628.41 Million INR | -859.392% |